Peptide News Digest

STAT LifeMD GLP-1 Safety Investigation, PCAC 3 Days Out, Q2 Earnings Season Preview

STAT investigation: LifeMD former employees allege patient safety compromised for GLP-1 volume; PCAC 3 days out; Q2 earnings season opens Aug 4-6 with Merck, Lilly, Novo.

3 stories · Covering industry, regulatory

Editor's Note

Monday's digest opens with a major STAT News investigation into LifeMD, a telehealth company Novo Nordisk lists on its website as a legitimate GLP-1 provider. Five former employees and two lawsuits filed by former top leaders allege the company pushed providers to review up to 25 patient cases per hour (roughly two minutes per patient) based only on electronic intake forms, prioritizing GLP-1 prescription volume over clinical screening and follow-up. Novo Nordisk lists LifeMD on its website as one of several telehealth partners for Wegovy and Ozempic access; LifeMD denies the allegations. The story extends the pattern documented by the June-July JAMA secret-shopper study (45 of 49 online sellers prescribed semaglutide or tirzepatide within a day with little clinical oversight) and the peptide-telehealth landscape work Peptide News Digest has tracked through 2026. On the regulatory side, the FDA Pharmacy Compounding Advisory Committee meets three days from now (Thursday July 23 through Friday July 24), with the written-comment docket FDA-2025-N-6895 closing at 11:59 PM ET on Wednesday July 22. Q2 2026 earnings season opens next week: Merck reports Tuesday August 4 with the LIPFENDRA (enlicitide) FDA approval milestone one week old, Eli Lilly reports Wednesday August 5 with Foundayo (orforglipron) first-quarter-out sales in focus, and Novo Nordisk reports Thursday August 6 with Wegovy pill trajectory in focus.

Industry

STAT News Investigation Monday July 20: Telemedicine Company LifeMD (Listed by Novo Nordisk on Its Website as a 'Legitimate Medicine Sourcing and Patient Support' Provider) Prioritized GLP-1 Prescription Volume Over Patient Safety According to Interviews With Five Former Employees Plus Two Lawsuits Filed by Former Top Leaders; Providers Reportedly Pressed to Review Up to 25 Patient Cases Per Hour (Approximately Two Minutes Per Case) Based Only on Electronic Intake Forms; Company Strenuously Denies the Allegations

STAT News published a major investigation Monday July 20, 2026 reporting that LifeMD, a US telehealth company promoted by Novo Nordisk as a partner for Wegovy and Ozempic access, has pushed clinicians to see more patients and dispense GLP-1 prescriptions more rapidly while providing what former workers describe as minimal screening and follow-up. Five former employees and two lawsuits filed by former top leaders allege that providers at LifeMD were pressed to review up to 25 patient cases per hour based only on the electronic intake forms patients themselves filled out, translating to approximately two minutes per case. Novo Nordisk currently lists LifeMD on its website as a partner that offers 'legitimate medicine sourcing and patient support' for people seeking GLP-1 drugs. LifeMD strenuously denies the allegations. The reporting extends the June-July concern set documented by the JAMA secret-shopper study (45 of 49 online sellers wrote semaglutide or tirzepatide prescriptions within a day with limited clinical oversight, July 7 digest coverage) and complements the peptide-telehealth-landscape reporting the site has tracked through 2026. The LifeMD story sits within the sprawling loosely-regulated GLP-1 telehealth industry that experts say has been boosted by Novo Nordisk and Eli Lilly as branded-drug demand expanded through 2025 and 2026.

#lifemd #novo-nordisk #glp-1 #telehealth #patient-safety #stat-news #wegovy #ozempic #prescription-oversight #clinical-screening
Regulatory

FDA Pharmacy Compounding Advisory Committee Peptide Meeting Three Days Out — Written-Comment Docket FDA-2025-N-6895 Closes Wednesday July 22 at 11:59 PM ET Before the Thursday-Friday July 23-24 Vote Opens at FDA White Oak Campus in Silver Spring, Maryland: Day 1 Reviews BPC-157, KPV, TB-500, and MOTS-c; Day 2 Reviews Emideltide (DSIP), Semax, and Epitalon; Career-Staff Briefing Documents Recommended Against Adding Any of the Seven Peptides to the 503A Bulks List While Panelist Composition Includes at Least Seven of Eight New Members With Documented Peptide-Industry Ties

The FDA Pharmacy Compounding Advisory Committee (PCAC) peptide meeting is three days out. Written-comment docket FDA-2025-N-6895 closes at 11:59 PM ET on Wednesday July 22, 2026; the two-day meeting opens Thursday July 23 and closes Friday July 24 at FDA's White Oak Campus in Silver Spring, Maryland. Day 1 (Thursday) reviews BPC-157, KPV, TB-500, and MOTS-c for 503A bulks-list eligibility. Day 2 (Friday) reviews DSIP (Emideltide), Semax, and Epitalon. The FDA career-staff briefing documents released June 29-30 recommended against adding any of the seven peptides to the 503A Bulks List, citing immunogenicity concerns, heavy-metal and microbial contamination in compounding-channel samples, mislabeled contents, and thin 503A historical use. The panel composition itself includes at least seven of eight new members named June 29 with documented ties to peptide-related businesses (per STAT News reporting). The written-comment docket has attracted filings from compounding-pharmacy industry groups (Alliance for Pharmacy Compounding, National Community Pharmacists Association, Outsourcing Facilities Association), consumer-safety voices (Public Citizen, Institute for Safe Medication Practices, Partnership for Safe Medicines), and academic scientists (UC Davis's Paul Knoepfler). A 'no' vote does not re-ban anything (the seven peptides came off Category 2 April 23), but a 'yes' vote requires FDA rulemaking (typically 6-18 months) before compounding pharmacies can act on it.

#pcac #fda #docket #bpc-157 #kpv #tb-500 #mots-c #emideltide #semax #epitalon #peptide-compounding #white-oak
Industry

Q2 2026 Earnings Season for the Peptide-and-Obesity Big Three Opens Next Week With Merck Reporting Tuesday August 4, Eli Lilly Wednesday August 5, and Novo Nordisk Thursday August 6: Analyst Focus Areas Include Merck's LIPFENDRA (Enlicitide) FDA Approval Milestone One Week Old at Report Time, Eli Lilly's Foundayo (Orforglipron) First-Quarter-Out US Retail Sales, Zepbound Growth Versus the Wegovy Pill Franchise, and Novo Nordisk's Response to Analyst Concerns About 2027 Wegovy List Price Reset to $675 That Would Represent a 50% Cut From the Current Level

Q2 2026 earnings season for the peptide-and-obesity big three opens next week. Merck reports Tuesday August 4 at 9:00 AM ET with the LIPFENDRA (enlicitide) FDA approval milestone (July 16) roughly one week old at report time; analyst focus areas include the pricing strategy at $10.50 per tablet ($315 per 30-day supply), the pharmacy-benefit distribution model, and initial payer coverage momentum. Eli Lilly reports Wednesday August 5 before market open; analyst focus areas include Foundayo (orforglipron) first-quarter-out US retail sales (Q1 sales were not yet in the books at the last report), Mounjaro and Zepbound growth versus the Wegovy pill franchise, and TRIUMPH-2 and TRIUMPH-3 readouts for retatrutide expected later in 2026. Novo Nordisk reports Thursday August 6; analyst focus areas include the Wegovy pill uptake beyond the 3 million-prescription milestone documented at ADA 2026 (June), the impact of Novo's price cuts in China and India, the Vivani implant partnership announced July 7, and the response to analyst concerns about the January 2027 Wegovy list price reset to $675 (a 50% cut from current levels). The three earnings prints together are expected to frame the second-half 2026 obesity market trajectory and the competitive positioning of the incretin, amylin, and macrocyclic peptide franchises against each other.

#merck #eli-lilly #novo-nordisk #q2-2026-earnings #lipfendra #foundayo #orforglipron #wegovy-pill #zepbound #mounjaro #obesity-drug-market